← Back to Search

Smartphone App for Vaping Cessation

N/A
Waitlist Available
Led By Jaimee Heffner
Research Sponsored by Fred Hutchinson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 3 months post-randomization
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a digital program called 'ACT on Vaping' that uses a smartphone app and text messages to help young adults quit vaping. The program targets young adults who use e-cigarettes and are at risk of nicotine addiction. The app and texts remind users to check their vaping habits and offer support to quit.

Who is the study for?
This trial is for young adults aged 18-30 in the US who use e-cigarettes at least weekly, own a smartphone (Android or iPhone), and have an email address. They must be willing to complete all study procedures and have a US mailing address.
What is being tested?
The trial is testing 'ACT on Vaping,' a digital program designed to help young adult e-cigarette users quit vaping. It involves using a smartphone app, receiving text messages, and completing surveys.
What are the potential side effects?
Since this intervention involves using a smartphone application and communication via text message rather than medication, traditional side effects are not expected. However, participants may experience stress or frustration related to quitting vaping.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in readiness to quit
Cotinine-confirmed 30-day point prevalence abstinence from all nicotine and tobacco
Overall treatment satisfaction rating
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (Act on Vaping app)Experimental Treatment3 Interventions
Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.
Group II: Arm II (Incentivized text message check-ins)Active Control2 Interventions
Participants receive incentivized text messages check-ins assessing their vaping status.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Smartphone app
2019
N/A
~190

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for nicotine addiction include pharmacologic therapies like nicotine replacement therapy (NRT), varenicline, and bupropion, which work by reducing withdrawal symptoms and cravings. NRT provides a controlled dose of nicotine, varenicline partially stimulates nicotine receptors, and bupropion affects neurotransmitters to reduce the urge to smoke. Behavioral therapies, such as digital behavioral therapy programs like ACT on Vaping, focus on changing habits and thought patterns associated with nicotine use through techniques like motivational interviewing and cognitive-behavioral strategies. These combined approaches are more effective as they address both the physical and psychological aspects of addiction, providing a comprehensive treatment plan for patients.
Electronic Cigarette Cessation in Youth and Young Adults: A Case Series.

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer CenterLead Sponsor
566 Previous Clinical Trials
1,342,441 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,556 Previous Clinical Trials
3,255,234 Total Patients Enrolled
15 Trials studying Nicotine Addiction
2,245 Patients Enrolled for Nicotine Addiction
Jaimee HeffnerPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium
5 Previous Clinical Trials
565 Total Patients Enrolled

Media Library

Smartphone Application (ACT on Vaping) Clinical Trial Eligibility Overview. Trial Name: NCT05897242 — N/A
Nicotine Addiction Research Study Groups: Arm I (Act on Vaping app), Arm II (Incentivized text message check-ins)
Nicotine Addiction Clinical Trial 2023: Smartphone Application (ACT on Vaping) Highlights & Side Effects. Trial Name: NCT05897242 — N/A
Smartphone Application (ACT on Vaping) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05897242 — N/A
~35 spots leftby Oct 2025